A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head and Neck Cancer Undergoing Concurrent Chemotherapy and Radiation.

Trial Profile

A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head and Neck Cancer Undergoing Concurrent Chemotherapy and Radiation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Fosaprepitant (Primary) ; Dexamethasone; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting; Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2017 Planned End Date changed from 1 Apr 2011 to 1 Feb 2011.
    • 18 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 04 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top